Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Rhona Johnston,1 Olalekan Uthman,2 Ewen Cummins,1 Christine Clar,3 Pamela Royle,2 Jill Colquitt,4 Bee Kang Tan,2 Andrew Clegg,5 Saran Shantikumar,2 Rachel Court,2 J Paul O’Hare,2 David McGrane,6 Tim Holt7 and Norman Waugh2*

1McMDC, Harrogate, UK  
2Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK  
3Berlin, Germany  
4Effective Evidence, Waterlooville, UK  
5University of Central Lancashire, Preston, UK  
6Queen Elizabeth University Hospital, Glasgow, UK  
7University of Oxford, Oxford, UK  

*Corresponding author

Corrigendum issued February 2018  
Corrigendum DOI: 10.3310/hta21020-c201802  
Original DOI: 10.3310/hta21020

This report should be referenced as follows:


Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/Clinical Medicine.
Corrigendum notice

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt and Norman Waugh

This paper1 is corrected as follows.

Empagliflozin (Jardiance, Merck & Co., Darmstadt, Germany) has been replaced with empagliflozin (Jardiance, Boehringer Ingelheim, Ingelheim, Germany/Eli Lilly and Company, Indianapolis, IN, USA).

Sitagliptin (Januvia, Boehringer Ingelheim, Bracknell, UK) has been replaced with sitagliptin (Januvia, Merck Sharp & Dohme Limited, Kenilworth, NJ, USA).

Reference